Immutep Ltd ADR Cash Flow Conversion Efficiency
Immutep Ltd ADR cash flow conversion efficiency. Based on the latest financial reports, Immutep Ltd ADR (IMMP) has a cash flow conversion efficiency ratio of -0.284x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.12 Million) by net assets ($98.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Immutep Ltd ADR (2008–2025)
Cash flow conversion efficiency of Immutep Ltd ADR from 2008 to 2025. This chart illustrates how Immutep Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View IMMP share price today for real-time trading data and today's change.
Immutep Ltd ADR Cash Flow Conversion Ratio Explained
Immutep Ltd ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Immutep Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immutep Ltd ADR ranked by their cash flow conversion efficiency. Also see IMMP market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Viet Nam Power Development JSC
VN:VPD
|
N/A |
|
Yusin Holding Corp
TW:4557
|
0.042x |
|
Kyungin Synthe
KO:012610
|
0.066x |
|
Chuwa Wool Industry Co Taiwan Ltd
TW:1439
|
0.032x |
|
Phenixfin Corporation
NASDAQ:PFX
|
0.000x |
|
Novogenia AG
XETRA:7V0
|
N/A |
|
LK CHEM
KQ:489500
|
0.040x |
|
Nova Minerals Limited
NYSE MKT:NVA
|
0.066x |
Annual Cash Flow Conversion Efficiency for Immutep Ltd ADR (2008–2025)
The table below shows the annual cash flow conversion efficiency of Immutep Ltd ADR from 2008 to 2025. Review IMMP financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $143.64 Million | $-62.05 Million | -0.432x | -135.12% |
| 2024-06-30 | $189.52 Million | $-34.82 Million | -0.184x | +30.12% |
| 2023-06-30 | $136.47 Million | $-35.88 Million | -0.263x | +18.17% |
| 2022-06-30 | $94.08 Million | $-30.23 Million | -0.321x | -33.47% |
| 2021-06-30 | $73.27 Million | $-17.64 Million | -0.241x | +26.04% |
| 2020-06-30 | $33.30 Million | $-10.84 Million | -0.326x | +48.07% |
| 2019-06-30 | $24.39 Million | $-15.29 Million | -0.627x | -170.19% |
| 2018-06-30 | $33.52 Million | $-7.78 Million | -0.232x | +27.64% |
| 2017-06-30 | $26.53 Million | $-8.51 Million | -0.321x | -0.12% |
| 2016-06-30 | $35.32 Million | $-11.31 Million | -0.320x | -1.53% |
| 2015-06-30 | $24.69 Million | $-7.79 Million | -0.315x | +49.92% |
| 2014-06-30 | $22.59 Million | $-14.23 Million | -0.630x | -14.85% |
| 2013-06-30 | $29.25 Million | $-16.04 Million | -0.548x | -6.56% |
| 2012-06-30 | $37.16 Million | $-19.12 Million | -0.515x | -190.62% |
| 2011-06-30 | $55.10 Million | $-9.76 Million | -0.177x | +54.00% |
| 2010-06-30 | $16.79 Million | $-6.46 Million | -0.385x | +62.96% |
| 2009-06-30 | $1.81 Million | $-1.88 Million | -1.039x | -76.06% |
| 2008-06-30 | $2.63 Million | $-1.55 Million | -0.590x | -- |
About Immutep Ltd ADR
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more